Skip to main content

Argyrophilic grain disease initially diagnosed as Parkinson's disease

  • Free for a limited time
  • Dementia
  • Case Study

AGD is an age-related tauopathy that contributes to cognitive decline. This case demonstrates that AGD should be included in the differential diagnosis of PD without dementia in older people.

Read more

Editor's Choice

CPAP therapy for OSA in Alzheimer’s disease

Obstructive sleep apnea is common in AD. Given its proven efficacy and feasibility, continuous positive airway pressure therapy should be offered in patients with comorbid AD and moderate–severe OSA.

20 years of lessons: anti-amyloid antibodies

Effective disease-modifying therapies are urgently needed to halt the progression of Alzheimer’s disease. What have we learned from developing monoclonal antibodies against amyloid beta?

Antihypertensive deprescribing may slow cognitive decline in nursing home residents

Strategically reducing or discontinuing antihypertensive medications in older nursing home residents may lessen their cognitive decline.

Recombinant shingles vaccine lowers dementia risk

Giving the recombinant shingles vaccine to adults aged 65 years or older is associated with a significantly lower risk for dementia in the 6 years after vaccination than the live alternative, which already offers some protection against the condition.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Advances in Alzheimer's

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Learn more

Case Studies

Argyrophilic grain disease initially diagnosed as Parkinson's disease

  • Free for a limited time
  • Dementia
  • Case Study

AGD is an age-related tauopathy that contributes to cognitive decline. This case demonstrates that AGD should be included in the differential diagnosis of PD without dementia in older people.

Unique presentation of memantine overdose

Hypertensive urgency and echolalia were the most striking symptoms of memantine overdose in an elderly man with mild dementia and hypertension. Early medication review with caregivers of people with dementia is key.

Expanding the phenotype of psychiatric-onset prodromal dementia with Lewy bodies

Core clinical features of dementia with Lewy bodies (DLB) are well-described, but clinical heterogeneity can lead to diagnostic delays. These three cases highlight the need to consider prodromal DLB as a differential of behavioural variant frontotemporal dementia.

At a glance: The TRAILBLAZER trials

A quick guide to the phase 2 and 3 clinical trials investigating donanemab as a treatment for Alzheimer’s disease.

Developed by: Springer Medicine
Read more

Current Reviews

GHRH and its analogues in central nervous system diseases

Growth hormone-releasing hormone (GHRH) is primarily produced by the hypothalamus and stimulates the release of growth hormone (GH) in the anterior pituitary gland, which subsequently regulates the production of hepatic insulin-like growth …

Exploring the role of HIF-1α on pathogenesis in Alzheimer’s disease and potential therapeutic approaches

Hypoxia-inducible factor 1α (HIF-1α) is a crucial transcription factor that regulates cellular responses to low oxygen levels (hypoxia). In Alzheimer’s disease (AD), emerging evidence suggests a significant involvement of HIF-1α in disease …

Cognitive impairment in patients on dialysis: can we prevent it?

Chronic kidney disease (CKD) is among the leading causes of morbidity and mortality as it affects more than 10% of the global adult population. Cognitive impairment has a positive correlation with the stage of CKD. It has been recorded in more …

Lecanemab in Alzheimer’s disease: a profile of its use

Lecanemab (also known as lecanemab-irmb in the USA; LEQEMBI®), an immunoglobulin (Ig)G1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid-β, is an emerging treatment option for patients with Alzheimer’s …

Episode 11: Cardiac rehabilitation in patients with frailty

The essentials of individualised rehab programmes for elderly patients with CVD and frailty

Nearly half of adults over the age of 65 have some degree of frailty, and over two-thirds have cardiac disease.

Dr. Eduard Shantsila discusses the importance of individualised rehabilitation programmes in these patients, to reduce morbidity and mortality, and improve quality of life.

Dr. Eduard Shantsila
Listen now

CME & eLearning

Panel Discussions | Vodcasts | News (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)

Emerging biomarkers and disease-modifying therapies for Alzheimer’s disease promise significant changes in how the condition is diagnosed and managed. Guide yourself through this transition with our education program, led by world renowned experts and covering the biggest international conferences.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME

Webcast | eLearning | Infographic (Link opens in a new window)

Expert insights into new data on novel PET biomarkers and tracers, with practical learning to detect early signs of Alzheimer's disease, advance diagnostic accuracy, and identify those who would benefit from disease-modifying therapies.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME

Further Reading

The Impact of Caregiving on Informal Caregivers of People with Dementia: Family Functioning, Burden, and Burnout

Caregiving is a complex occupation, with a significant impact for informal caregivers (IC). Stress-process models propose a framework that considers that this impact depends on primary and secondary stressors, but also on the IC situation …

The Association Between Constipation and Positron Emission Tomography and Blood-Based Biomarkers in Older Cognitively Unimpaired Adults with Higher Amyloid-β Burden

Alzheimer’s disease (AD), as the most common cause of dementia, accounts for 60–80% of cases. AD and related dementias contribute to a progressive decline in daily activities in older adults [ 1 ]. AD is a continuum starting with a prolonged phase …

Mortality of alzheimer’s disease in Italy from 1980 to 2015

With more than 55 million people affected and nearly 10 million new cases per year, dementia is one of the most widespread neurological conditions and the seventh cause of death worldwide [ 1 , 2 ]. In Europe, it is estimated that almost 9 millions …

Family history of dementia and brain health in childhood and middle age: a prospective community-based study

  • Open Access
  • Dementia
  • NEURO-EPIDEMIOLOGY

We aimed to determine the association of family history of dementia with structural brain measures and cognitive performance in childhood and mid-life adulthood. We studied 1,259 parents (mean age: 47.3 years, range 31.9–67.4) and 866 of their …

Related topics

CPAP therapy for OSA in Alzheimer’s disease

Obstructive sleep apnea is common in AD. Given its proven efficacy and feasibility, continuous positive airway pressure therapy should be offered in patients with comorbid AD and moderate–severe OSA.

Read more